Alaunos Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alaunos Therapeutics, Inc.
When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?
There have been no biopharma initial public offerings in the US since 12 January while the industry’s valuations have plummeted by double digits since the start of 2022. Nevertheless, venture capital investment continues at a fast pace and there have been some follow-on public offerings.
The biopharma market has been highly active throughout the COVID-19 pandemic with a substantial focus on strategic alliances between 2020-H1 2021. Partnership deals present exciting liquidity and risk mitigation opportunities for early-stage companies. Small molecules still comprise the largest segment of partnered drugs, but alliances for other modalities are on the rise.
J&J failed to convince BBB National Program’s appeals panel a 2008 NAD decision supporting its “#1 dermatologist recommended” claim for Neutrogena should preclude another review. Panel says market has changed in 12 years since review of Unilever challenge and L’Oreal could make its own challenge.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Eden Biocell, Ltd, Ziopharm Oncology, Inc.